- $4.09m
- -$1.01m
- $8.74m
- 40
- 66
- 26
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.63 | ||
| Price to Tang. Book | 0.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -138.1% | ||
| Return on Equity | -218.13% | ||
| Operating Margin | -115.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.44 | 7.92 | 8.54 | 8.86 | 8.74 | 10.54 | 13.69 | 9.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Directors
- John Erb CHM (72)
- Nestor Jaramillo PRE (63)
- George Montague CFO (56)
- Neil Ayotte SVP
- Paul Wotta CAO (64)
- Warren Watson LED (68)
- Steven Brandt IND (65)
- Maria Costanzo IND (66)
- Jon Salveson IND (56)
- Gregory Waller IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 22nd, 2002
- Public Since
- February 16th, 2012
- No. of Shareholders
- 1
- No. of Employees
- 38
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 4,373,968
- Address
- 12988 Valley View Rd, EDEN PRAIRIE, 55344-3657
- Web
- https://www.nuwellis.com/
- Phone
- +1 9523454200
- Auditors
- BAKER TILLY US LLP
Upcoming Events for NUWE
Nuwellis Inc Annual Shareholders Meeting
Nuwellis Inc Annual Shareholders Meeting
Q2 2025 Nuwellis Inc Earnings Release
Similar to NUWE
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Nuwellis share price?
As of Today at 22:23 UTC, shares in Nuwellis are trading at $0.93. This share price information is delayed by 15 minutes.
How has the Nuwellis share price performed this year?
Shares in Nuwellis last closed at $0.93 and the price had moved by -90.39% over the past 365 days. In terms of relative price strength the Nuwellis share price has underperformed the S&P500 Index by -90.96% over the past year.
What are the analyst and broker recommendations for Nuwellis?
The overall consensus recommendation for Nuwellis is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Nuwellis dividend yield?
Nuwellis does not currently pay a dividend.
Does Nuwellis pay a dividend?
Nuwellis does not currently pay a dividend.
When does Nuwellis next pay dividends?
Nuwellis does not currently pay a dividend.
How do I buy Nuwellis shares?
To buy shares in Nuwellis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nuwellis?
As of the previous close price of $0.93, shares in Nuwellis had a market capitalisation of $4.09m.
Where are Nuwellis shares listed?
Here are the trading details for Nuwellis:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NUWE
What kind of share is Nuwellis?
Based on an overall assessment of its quality, value and momentum Nuwellis is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nuwellis share price forecast for 2025?
The analyst consensus target price for shares in Nuwellis is $13.00. That is 1291.12% above the last closing price of $0.93.
Analysts covering Nuwellis currently have a consensus Earnings Per Share (EPS) forecast of -$2.06 for the next financial year.
Find out moreWhat is the trend in the Nuwellis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nuwellis. Over the past six months, its share price has underperformed the S&P500 Index by -30.03%.
As of the last closing price of $0.93, shares in Nuwellis were trading -42.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nuwellis PE Ratio?
The Nuwellis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nuwellis?
Nuwellis' management team is headed by:
- John Erb - CHM
- Nestor Jaramillo - PRE
- George Montague - CFO
- Neil Ayotte - SVP
- Paul Wotta - CAO
- Warren Watson - LED
- Steven Brandt - IND
- Maria Costanzo - IND
- Jon Salveson - IND
- Gregory Waller - IND